Cointime

EnGen Bio

company

About

EnGen Bio is a development-stage biotechnology company that pioneers a new approach to preventing and treating influenza.

  • 11 - 50

Highlights

Total Funding Amount
$180K
Funding Rounds
1
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
$180K
Industries
Biotechnology,Health Care,Health Diagnostics,Life Science
Founded date
Jan 1, 2016
Number Of Employee
11 - 50
Operating Status
Active

EnGen Bio is a development-stage biotechnology company that pioneers a new approach to preventing and treating influenza. It believes that it has identified a candidate Universal Type A Influenza vaccine. Influenza drugs and vaccines are unique because there is sufficient government funding available to develop these assets well into human clinical trials, and possibly to market. EnGen Bio is aggressively pursuing this and similar opportunities.

It is founded in 2017 and is headquartered in Redwood City, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$180K
EnGen Bio has raised a total of $180K in funding over 2 rounds. Their latest funding was raised on Nov 27, 2012 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 27, 2012 Grant $180K 1 National Science Foundation — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
EnGen Bio is funded by 1 investors. National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant
Cointime
เนื้อหา
บริษัท